MedTrace Logo

A Study for Post-Marketing Surveillance of Nesina® Tablet Monotherapy or Combination Therapy in Participants With Type 2 Diabetes (T2DM) in South Korea

NCT04980040 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3623

Last updated 2022-04-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate safety by determining the incidence rates of all adverse events (AEs) including serious adverse events (SAEs)/serious adverse drug reactions (ADRs), unexpected AEs and ADRs that are not reflected in the precautions for use, ADRs already known, non-serious ADRs and other safety related information among participants who have received alogliptin for type 2 diabetes mellitus.

Conditions

Interventions

DRUG

Alogliptin Benzoate

Alogliptin benzoate tablets

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-19
Primary Completion
2019-08-30
Completion
2019-08-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04980040 on ClinicalTrials.gov